Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
Phase 4
Terminated
- Conditions
- Parkinson Disease
- Registration Number
- NCT00174239
- Lead Sponsor
- Pfizer
- Brief Summary
The study will assess the relative benefit of cabergoline vs carbidopa/levodopa therapy in treating nighttime problems of Parkinson Disease.
- Detailed Description
The trial was terminated prematurely June 26, 2005 due to the inability to re-supply study drug for the planned number of subjects. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 220
Inclusion Criteria
- Idiopathic Parkinson Disease
- Must be experiencing sleep akinesia
Exclusion Criteria
- Current treatment with other dopamine agonists
- Nocturnal hallucinations
- Dementia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method PDSS, UPDRS
- Secondary Outcome Measures
Name Time Method CGI, PGI, Epworth Sleepiness Scale, PDQ-39
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇪🇸Sevilla, Spain